IDL Diagnostics - Still under the radar

Redeye reviews the case for IDL Diagnostics, and while we down our medium-term sales forecasts, we reconsider our long-term estimates. We lengthen our DCF period ending in 2035e (from 2032e) and assume higher market penetrations for its key products.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/